![Alex Baldwin PhD, BSc (Hons), CChem, MRSC](https://profiles-cardiff.imgix.net/attachments/6702?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Alex Baldwin
PhD, BSc (Hons), CChem, MRSC
Research Fellow in Medicinal Chemistry
Overview
Alex Baldwin is a Research Fellow in Medicinal Chemistry and team leader at the Medicines Discovery Institute, which aims to translate new discoveries in disease mechanisms into developing novel therapeutics. Over the past 10 years, Alex has contributed to the discovery of a number of small molecule drug candidates that have entered into preclinical development, particularly in the CNS area. Alex leads medicinal chemistry teams across Cardiff and industry collaborators to drive optimised drug candidates to treat diseases of significant unmet clinical need.
Alex obtained his degree in Biological and Medicinal Chemistry from the University of Exeter, his PhD in Medicinal Chemistry from the University of Manchester and has more than 10 peer reviewed publications and patents.
Publication
2025
- Baldwin, A. G. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat fragile X syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Baldwin, A. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat Fragile X Syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
2022
- Ward, S. et al. 2022. Heteroaryl compounds useful in the treatment of cognitive disorders. WO2022/234271 [Patent].
- Collins, R. et al. 2022. Comparative analysis of small-molecule limk1/2 inhibitors: chemical synthesis, biochemistry, and cellular activity. Journal of Medicinal Chemistry (10.1021/acs.jmedchem.2c00751)
2020
- Brough, D., Allan, S. M., Freeman, S. and Baldwin, A. G. 2020. Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors. US 10570157 [Patent].
2018
- Alnabulsi, S. et al. 2018. Evaluation of analogues of furan-amidines as inhibitors of NQO2. Biorganic and Medicinal Chemistry Letters 28(8), pp. 1292-1297. (10.1016/j.bmcl.2018.03.025)
- Redondo-Castro, E. et al. 2018. Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses. Scientific Reports 8(1), article number: 5667. (10.1038/s41598-018-24029-3)
- Baldwin, A., Bevan, J., Brough, D., Ledder, R. and Freeman, S. 2018. Synthesis and antibacterial activities of enamine derivatives of dehydroacetic acid. Medicinal Chemistry Research 27(3), pp. 884-889. (10.1007/s00044-017-2110-8)
- Baldwin, A., Tapia, V. S., Swanton, T., White, C. S., Beswick, J. A., Brough, D. and Freeman, S. 2018. Design, synthesis and evaluation of oxazaborine inhibitors of the NLRP3 inflammasome. ChemMedChem 13(4), pp. 312-320. (10.1002/cmdc.201700731)
2017
- Baldwin, A. et al. 2017. Boron-based inhibitors of the NLRP3 inflammasome. Cell Chemical Biology 24(11), pp. 1321-1335., article number: e5. (10.1016/j.chembiol.2017.08.011)
- Brough, D., Allan, S. M., Freeman, S. and Baldwin, A. G. 2017. Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors. WO/2017/017469 [Patent].
2016
- Daniels, M. J. D. et al. 2016. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nature Communications 7, article number: 12504. (10.1038/ncomms12504)
2015
- Baldwin, A., Brough, D. and Freeman, S. 2015. Inhibiting the inflammasome: a chemical perspective. Journal of Medicinal Chemistry 59(5), pp. 1691-1710. (10.1021/acs.jmedchem.5b01091)
Articles
- Baldwin, A. G. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat fragile X syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Baldwin, A. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat Fragile X Syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Collins, R. et al. 2022. Comparative analysis of small-molecule limk1/2 inhibitors: chemical synthesis, biochemistry, and cellular activity. Journal of Medicinal Chemistry (10.1021/acs.jmedchem.2c00751)
- Alnabulsi, S. et al. 2018. Evaluation of analogues of furan-amidines as inhibitors of NQO2. Biorganic and Medicinal Chemistry Letters 28(8), pp. 1292-1297. (10.1016/j.bmcl.2018.03.025)
- Redondo-Castro, E. et al. 2018. Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses. Scientific Reports 8(1), article number: 5667. (10.1038/s41598-018-24029-3)
- Baldwin, A., Bevan, J., Brough, D., Ledder, R. and Freeman, S. 2018. Synthesis and antibacterial activities of enamine derivatives of dehydroacetic acid. Medicinal Chemistry Research 27(3), pp. 884-889. (10.1007/s00044-017-2110-8)
- Baldwin, A., Tapia, V. S., Swanton, T., White, C. S., Beswick, J. A., Brough, D. and Freeman, S. 2018. Design, synthesis and evaluation of oxazaborine inhibitors of the NLRP3 inflammasome. ChemMedChem 13(4), pp. 312-320. (10.1002/cmdc.201700731)
- Baldwin, A. et al. 2017. Boron-based inhibitors of the NLRP3 inflammasome. Cell Chemical Biology 24(11), pp. 1321-1335., article number: e5. (10.1016/j.chembiol.2017.08.011)
- Daniels, M. J. D. et al. 2016. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nature Communications 7, article number: 12504. (10.1038/ncomms12504)
- Baldwin, A., Brough, D. and Freeman, S. 2015. Inhibiting the inflammasome: a chemical perspective. Journal of Medicinal Chemistry 59(5), pp. 1691-1710. (10.1021/acs.jmedchem.5b01091)
Patents
- Ward, S. et al. 2022. Heteroaryl compounds useful in the treatment of cognitive disorders. WO2022/234271 [Patent].
- Brough, D., Allan, S. M., Freeman, S. and Baldwin, A. G. 2020. Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors. US 10570157 [Patent].
- Brough, D., Allan, S. M., Freeman, S. and Baldwin, A. G. 2017. Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors. WO/2017/017469 [Patent].
Research
Alex's research interests lie in translational drug discovery and he is driven by a strong desire to make a significant difference to patients and their families lives by developing novel drug candidates (either best-in-class or first-in-class) for clinical development. He is engaged in several medicinal chemistry programmes, leading multidisciplinary teams across Cardiff and with industrial collaborators.
Alex has over 10 years of drug discovery experience, primarily in the neuroscience field. His research portfolio includes a number of different types of drug targets (kinases, receptors and ion channels) covering a range of neurodegenerative diseases (Alzheimer's and Huntington's disease), psychiatric disorders (schizophrenia, generalised anxiety disorder) and genetic disorders (Fragile X syndrome, Niemann-Pick disease type C). He has considerable expertise in all phases of preclinical drug discovery, from target identification/validation and hit-to-lead through to early and late-stage multi-parameter lead optimisation.
Active projects:
- Developing novel lysosomal modulators to treat neurodegenerative disorders (in collaboration with Astex Pharmaceuticals)
- Discovery of novel LIMK1 inhibitors and LIMK PROTACs for the treatment of Fragile X syndrome
- Proof-of-concept for α5-GABAAR PAMs in the treatment of psychosis
Current drug discovery portfolio:
- α5-GABAAR NAMs for the treatment of cognitive impairment associated with Huntington's disease
- Anxioselective GABAAR modulators for the treatment of anxiety disorders
- PROTAC molecules targeting METTL3 for cancer
- Boron-based NLRP3 inhibitors for the treatment of neuroinflammation associated with Alzheimer's disease (in collaboration with Dementia Consortium)
- Fenamate NSAIDs as NLRP3 inflammasome inhibitors to treat Alzheimer's disease
- Novel dehydroacetic acid derivatives as improved antimicrobial agents
Biography
Alex has a BSc (with Honours) in Biological and Medicinal Chemistry from University of Exeter and a PhD in Medicinal Chemistry from The University of Manchester, under the supervision of Dr. Sally Freeman and Prof. David Brough. His PhD research focused on discovery and development of a novel class of boron-based inhibitors of the NLRP3 inflammasome, an exciting therapeutic target implicated in a wide range of diseases including gout, atherosclerosis, type 2 diabetes and Alzheimer's disease.
In 2018, Alex joined the Medicines Discovery Institute as a postdoctoral research associate where he designed and synthesised complex target molecules on a variety of CNS drug discovery projects. Alex grew his research portfolio during this period and is associated with a number of successful medicinal chemistry programmes, including α5-GABAAR modulators for the treatment of schizophrenia and cognitive impairment associated with Huntington's disease.
Alex became Research Fellow in 2023 where he currently leads a medicinal chemistry team dedicated to the discovery and development of novel small molecule therapeutics for CNS disorders in a £2.8 million collaboration with Astex Pharmaceuticals. He is also leading a programme developing LIMK1 inhibitors and LIMK PROTACs for Fragile X syndrome.
Alex has received Chartered Chemist status and is a Member of the Royal Society of Chemistry (MRSC).
Contact Details
Research themes
Specialisms
- Translational Drug Discovery
- Medicinal and biomolecular chemistry
- Organic chemistry